Ovarian Cancer and Us - best viewed in FIREFOX

Search: this blog, links from posts and the web.....

Loading...

Friday, March 04, 2011

(full free access) Cell - Hallmarks of Cancer: The Next Generation - references to ovarian cancer




update with patient/consumer/public responses: Patients With Unrealistic Expectations - NYTimes.com




Genetics Company Myriad May Shift From Patents To Proprietary Data | Intellectual Property Watch




media: (mother is ovarian cancer survivor) Patrick Dempsey puts on his car racing leathers for cancer charity event at Miami Speedway | Mail Online




Business Line : Companies News : Strides gets EU nod to market ovarian cancer drug (generic Carboplatin)




Mutation deep within an intron of MSH2 causes Lynch syndrome



".......... thus highlighting the need for more extensive sequencing approaches in families where routine procedures fail to find a mutation."

CHSPR - University of British Columbia: 2011 Health Policy Conference BOOMERANGST: Myths and Realities about health care for an aging population (Lewis/Berwick quote...)



Note: 

1) includes influence of cancer/aging/demographics

2)  referenced via Hsien Seow presentation:
"Inbalance. Not by chance.
(Don Berwick quote: every system is perfectly designed to produce exactly the results it gets.  A systematic issue.)
We have a system that provide PC only when patients are “dying” or at EOL. – actively dying."

......................................................................

Day 1: February 22, 2011


8:30 am -- Welcome from the co-chairs

Patricia Baird, University of British Columbia Audio Slides
9:00 am -- Opening Plenary: Myths and Realities about demographics

Jay Olshansky, University of Illinois Audio Slides

Alan Cassels, University of Victoria Audio Slides
11:00 am -- Session I: Will aging bankrupt the health care system?

Michael Wolfson, University of Ottawa Audio Slides

Stephen Duckett, University of Alberta Audio Slides
12:00 pm -- Lunch Presentation Audio Slides



1:15 pm -- Session II: Is it possible (or sensible) to differentiate health and social care?

John Sloan, University of British Columbia Audio Slides

Jon Glasby, University of Birmingham Audio Slides

Vasanthi Srinivasan, Ontario Health Systems Strategy Division Audio Slides
2:45 pm -- Session III: Aging in (what) place?

Carole Estabrooks, Canada Research Chair in Knowledge Translation Audio Slides

Tine Rostgaard, Danish National Institute of Social Research Audio Slides

Neena Chappell, Department of Sociology at the University of Victoria Audio Slides

Day 2: February 23, 2011


8:30 am -- Session IV: Whose death is it anyway?

Hsien Seow, Cancer Care Ontario Research Chair Audio Slides

Dr. Michael Dolan, Internal Medicine Physician Audio Slides

Hon. Sharon Carstairs, P.C., Liberal Senate Forum Audio
10:30 am -- Session V: Is aging a disease?

Matthew Farrer, Centre for Molecular Medicine and Therapeutics Audio Slides

Ross Upshur, University of Toronto Joint Centre for Bioethics Audio Slides
12:00 pm -- Closing Plenary Speaker

Steven Lewis, Health Care Consultant, Saskatoon Audio

Cochrane review: Interventions for preventing neuropathy caused by cisplatin and related compounds



AUTHORS' CONCLUSIONS: At present, the data are insufficient to conclude that any of the purported chemoprotective agents (acetylcysteine, amifostine, calcium and magnesium, diethyldithiocarbamate, glutathione, Org 2766, oxycarbazepine, or Vitamin E) prevent or limit the neurotoxicity of platin drugs among human patients.